{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:17:00Z","timestamp":1788970620948,"version":"build-2803163510"},"reference-count":15,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"7","license":[{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2023.284635","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T03:06:30Z","timestamp":1709175990000},"page":"2331-2336","source":"Crossref","is-referenced-by-count":1,"title":["Health-related quality of life in relapsed\/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study"],"prefix":"10.3324","volume":"109","author":[{"given":"Fredrik H.","family":"Schjesvold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sossana","family":"Delimpasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Robak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Coriu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waldemar","family":"Tomczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludek","family":"Pour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Spicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios-Athanasios","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamas","family":"Masszi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia G.","family":"Chernova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sandberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Thuresson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Norin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaas A.","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,2,29]]},"reference":[{"key":"63768","doi-asserted-by":"crossref","unstructured":"LeBlanc MR, Hirschey R, Leak Bryant A, LeBlanc TW, Smith SK. How are patient-reported outcomes and symptoms being measured in adults with relapsed\/refractory multiple myeloma? A systematic review. Qual Life Res. 2020; 29(6):1419-1431.","DOI":"10.1007\/s11136-019-02392-6"},{"key":"63769","doi-asserted-by":"crossref","unstructured":"Engelhardt M, Ihorst G, Singh M. Real-world evaluation of health-related quality of life in patients with multiple myeloma from Germany. Clin Lymphoma Myeloma Leuk. 2021; 21(2):e160-e175.","DOI":"10.1016\/j.clml.2020.10.002"},{"key":"63770","doi-asserted-by":"crossref","unstructured":"Richardson PG, Oriol A, Larocca A. Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma. J Clin Oncol. 2021; 39(7):757-767.","DOI":"10.1200\/JCO.20.02259"},{"key":"63771","unstructured":"Schjesvold FH, Dimopoulos MA, Delimpasi S. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. Lancet Haematol. 2022; 9(2):e98-e110."},{"key":"63772","doi-asserted-by":"crossref","unstructured":"Sonneveld P, Richardson PG, Ludwig H. Benefit versus risk assessment of melflufen and dexamethasone in relapsed\/ refractory multiple myeloma: analyses from longer follow-up of the OCEAN and HORIZON studies. Clin Lymphoma Myeloma Leuk. 2023; 23(9):P687-696.","DOI":"10.1016\/j.clml.2023.05.004"},{"key":"63773","doi-asserted-by":"crossref","unstructured":"Richardson PG, Bringhen S, Voorhees P. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study. Lancet Haematol. 2020; 7(5):e395-e407.","DOI":"10.1016\/S2352-3026(20)30044-2"},{"key":"63774","doi-asserted-by":"crossref","unstructured":"Larocca A, Leleu X, Touzeau C. Patient-reported outcomes in relapsed\/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the phase II HORIZON study. Br J Haematol. 2022; 196(3):639-648.","DOI":"10.1111\/bjh.17887"},{"key":"63775","doi-asserted-by":"crossref","unstructured":"Song KW, Dimopoulos MA, Weisel KC. Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and\/or refractory multiple myeloma. Haematologica. 2015; 100(2):e63-67.","DOI":"10.3324\/haematol.2014.112557"},{"key":"63776","unstructured":"Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 Scoring Manual. 3rd ed. Brussels: European Organisation for Research and Treatment of Cancer. 2001. Publisher Full Text|"},{"key":"63777","doi-asserted-by":"crossref","unstructured":"Aaronson NK, Ahmedzai S, Bergman B. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85(5):365-376.","DOI":"10.1093\/jnci\/85.5.365"},{"key":"63778","doi-asserted-by":"crossref","unstructured":"EuroQol G. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990; 16(3):199-208.","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"63779","doi-asserted-by":"crossref","unstructured":"Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998; 16(1):139-144.","DOI":"10.1200\/JCO.1998.16.1.139"},{"key":"63780","doi-asserted-by":"crossref","unstructured":"Ojo AS, Araoye MO, Ali A, Sarma R. The impact of current therapeutic options on the health-related quality of life of patients with relapse\/refractory multiple myeloma: a systematic review of clinical studies. J Cancer Surviv. 2024; 18:673-697.","DOI":"10.1007\/s11764-023-01332-1"},{"key":"63781","doi-asserted-by":"crossref","unstructured":"Terpos E, Dimopoulos MA, Boccadoro M. Health-related quality of life in patients with relapsed\/refractory multiple myeloma treated with pomalidomide and dexamethasone +\/-subcutaneous daratumumab: patient-reported outcomes from the APOLLO trial. Am J Hematol. 2022; 97(4):481-490.","DOI":"10.1002\/ajh.26480"},{"key":"63782","unstructured":"Popat R, Lonial S, Lee HC. DREAMM-2: belantamab mafodotin effect on disease symptoms and health-related quality of life in patients with relapsed\/refractory multiple myeloma (RRMM). Presented at the European Hematology Association (EHA) Virtual Congress, 2020; Abstract EP1746. 2023."}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284635\/76717","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284635\/77224","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284635\/76717","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:53:26Z","timestamp":1788969206000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":15,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284635","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,29]]}}}